In a significant step forward for the ocular melanoma community, TrilliumBiO and Oncobit have announced a new partnership that promises to transform the way uveal melanoma is monitored and managed in the United States. For patients, caregivers, and clinicians—including those we support every day at A Cure In Sight—this collaboration introduces a long-awaited expansion of precision tools that can help guide treatment decisions and improve long-term outcomes.

Uveal melanoma remains a rare and challenging cancer, often diagnosed early but monitored with limited tools once treatment begins. Traditional surveillance relies heavily on imaging, which can miss subtle molecular changes. The newly announced partnership directly addresses this unmet need by bringing Oncobit’s Personalized Monitoring (PM) platform—already studied extensively in Europe—to TrilliumBiO’s national, multi-accredited laboratory network.

What This Means for Patients Living With Ocular Melanoma

At the heart of this collaboration is circulating tumor DNA (ctDNA) monitoring, a rapidly advancing technology that has shown tremendous promise in predicting treatment response and disease progression. According to multiple studies referenced in the press release, ctDNA dynamics assessed with Oncobit™ PM may serve as a powerful prognostic tool for metastatic uveal melanoma. This is particularly meaningful for patients who often struggle with the anxiety of uncertainty between scans.

By expanding access across the U.S., TrilliumBiO and Oncobit are helping close a major gap in personalized cancer care. Patients will have access to more frequent, sensitive monitoring that may detect molecular changes long before they appear on imaging—providing earlier opportunities for intervention and more informed decisions about clinical trials and therapies.

A Partnership Rooted in Precision and Patient Impact

TrilliumBiO brings expertise in developing and validating diagnostic tests that transition smoothly from research to real-world use. Their ability to scale advanced assays across a nationwide laboratory infrastructure makes them the ideal partner to introduce Oncobit’s solution to U.S. clinicians and cancer centers.

Oncobit, a Swiss precision oncology company, has developed an innovative, data-driven monitoring platform that integrates liquid biopsy testing with sophisticated cloud-based interpretation software. This allows oncologists to consistently track ctDNA levels, compare molecular signatures over time, and use that information to guide therapy.

Together, the companies aim to offer:

  • Earlier detection of progression using ctDNA

  • MRD-guided treatment decision support

  • More personalized and responsive monitoring

  • A scalable, standardized approach to precision oncology

This partnership is more than a technology upgrade—it is a meaningful shift toward patient-centered care in a space where options remain limited.

Why This Matters for the Ocular Melanoma Community

For years, patients and advocates have pushed for better monitoring tools that allow earlier intervention and more clarity during treatment. With metastatic ocular melanoma carrying significant risks and limited approved therapies, improved monitoring could become a crucial part of extending survival and quality of life.

At A Cure In Sight, we hear every day from patients who crave clearer information about their disease. Anxiety between scans—often referred to as “scanxiety”—is a real emotional burden. Tools that help detect molecular changes sooner may give patients:

  • A better understanding of whether treatment is working

  • A chance to explore new therapies sooner

  • Enhanced confidence in their care team’s decisions

  • More peace of mind between imaging appointments

This collaboration aligns with our mission to support patients through hope, education, and improved access to care.

Looking Ahead

As precision oncology continues to evolve, partnerships like this one help ensure that patients with rare cancers are not left behind. By making ctDNA-based monitoring more available across the U.S., TrilliumBiO and Oncobit are contributing to a future where ocular melanoma patients receive truly personalized, data-driven care.

We will continue following developments closely and sharing updates with our community, especially as new diagnostic tools, biomarkers, and treatment strategies emerge.

For patients, caregivers, and clinicians seeking resources or support, A Cure In Sight remains committed to helping you navigate every step of your ocular melanoma journey.